180 related articles for article (PubMed ID: 35643589)
1. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Siefker-Radtke AO; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D; Hoch U; Choudhury A; Yu D; Currie SL; Tagliaferri MA; Zalevsky J; Hurwitz ME; Tannir NM
Eur Urol; 2022 Oct; 82(4):365-373. PubMed ID: 35643589
[TBL] [Abstract][Full Text] [Related]
2. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Tannir NM; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D; Hoch U; Choudhury A; Yu D; Currie SL; Tagliaferri MA; Zalevsky J; Siefker-Radtke AO; Hurwitz ME
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444058
[TBL] [Abstract][Full Text] [Related]
3. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Diab A; Gogas H; Sandhu S; Long GV; Ascierto PA; Larkin J; Sznol M; Franke F; Ciuleanu TE; Pereira C; Muñoz Couselo E; Bronzon Damian F; Schenker M; Perfetti A; Lebbe C; Quéreux G; Meier F; Curti BD; Rojas C; Arriaga Y; Yang H; Zhou M; Ravimohan S; Statkevich P; Tagliaferri MA; Khushalani NI
J Clin Oncol; 2023 Oct; 41(30):4756-4767. PubMed ID: 37651676
[TBL] [Abstract][Full Text] [Related]
4. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Diab A; Tykodi SS; Daniels GA; Maio M; Curti BD; Lewis KD; Jang S; Kalinka E; Puzanov I; Spira AI; Cho DC; Guan S; Puente E; Nguyen T; Hoch U; Currie SL; Lin W; Tagliaferri MA; Zalevsky J; Sznol M; Hurwitz ME
J Clin Oncol; 2021 Sep; 39(26):2914-2925. PubMed ID: 34255535
[TBL] [Abstract][Full Text] [Related]
5. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Huddart RA; Siefker-Radtke AO; Balar AV; Bilen MA; Powles T; Bamias A; Castellano D; Khalil MF; Van Der Heijden MS; Koshkin VS; Pook DW; Özgüroğlu M; Santiago L; Zhong B; Chien D; Lin W; Tagliaferri MA; Loriot Y
Future Oncol; 2021 Jan; 17(2):137-149. PubMed ID: 32938232
[TBL] [Abstract][Full Text] [Related]
6. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
[TBL] [Abstract][Full Text] [Related]
7. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO; Grün CB; Niegisch G; Pichler M; Roghmann F; Schmitz-Dräger B; Baretton G; Schmitz M; Bolenz C; Foller S; Leucht K; Schumacher U; Schostak M; Meran J; Loidl W; Zengerling F
Lancet Oncol; 2023 Apr; 24(4):347-359. PubMed ID: 36868252
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS; Sonpavde G; Powles T; Necchi A; Burotto M; Schenker M; Sade JP; Bamias A; Beuzeboc P; Bedke J; Oldenburg J; Chatta G; Ürün Y; Ye D; He Z; Valderrama BP; Ku JH; Tomita Y; Filian J; Wang L; Purcea D; Patel MY; Nasroulah F; Galsky MD;
N Engl J Med; 2023 Nov; 389(19):1778-1789. PubMed ID: 37870949
[TBL] [Abstract][Full Text] [Related]
9. Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).
Tannir NM; Formiga MN; Penkov K; Kislov N; Vasiliev A; Gunnar Skare N; Hong W; Dai S; Tang L; Qureshi A; Zalevsky J; Tagliaferri MA; George D; Agarwal N; Pal S
J Clin Oncol; 2024 Jun; ():JCO2302082. PubMed ID: 38838287
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
Girardi DM; Niglio SA; Mortazavi A; Nadal R; Lara P; Pal SK; Saraiya B; Cordes L; Ley L; Ortiz OS; Cadena J; Diaz C; Bagheri H; Redd B; Steinberg SM; Costello R; Chan KS; Lee MJ; Lee S; Yu Y; Gurram S; Chalfin HJ; Valera V; Figg WD; Merino M; Toubaji A; Streicher H; Wright JJ; Sharon E; Parnes HL; Ning YM; Bottaro DP; Cao L; Trepel JB; Apolo AB
Clin Cancer Res; 2022 Apr; 28(7):1353-1362. PubMed ID: 35031545
[TBL] [Abstract][Full Text] [Related]
11. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
12. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Eggermont AM; Ascierto PA; Khushalani NI; Schadendorf D; Boland G; Weber J; Lewis KD; Johnson D; Rivalland G; Khattak A; Majem M; Gogas H; Long GV; Currie SL; Chien D; Tagliaferri MA; Carlino MS; Diab A
Future Oncol; 2022 Mar; 18(8):903-913. PubMed ID: 35073733
[TBL] [Abstract][Full Text] [Related]
13. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.
Khushalani NI; Diab A; Ascierto PA; Larkin J; Sandhu S; Sznol M; Koon HB; Jarkowski A; Zhou M; Statkevich P; Geese WJ; Long GV
Future Oncol; 2020 Oct; 16(28):2165-2175. PubMed ID: 32723187
[TBL] [Abstract][Full Text] [Related]
14. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
Apolo AB; Nadal R; Girardi DM; Niglio SA; Ley L; Cordes LM; Steinberg SM; Sierra Ortiz O; Cadena J; Diaz C; Mallek M; Davarpanah NN; Costello R; Trepel JB; Lee MJ; Merino MJ; Bagheri MH; Monk P; Figg WD; Gulley JL; Agarwal PK; Valera V; Chalfin HJ; Jones J; Streicher H; Wright JJ; Ning YM; Parnes HL; Dahut WL; Bottaro DP; Lara PN; Saraiya B; Pal SK; Stein MN; Mortazavi A
J Clin Oncol; 2020 Nov; 38(31):3672-3684. PubMed ID: 32915679
[TBL] [Abstract][Full Text] [Related]
15. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel P; Sweis RF; Bupathi M; Heath E; Goodman OB; Hoimes CJ; Milowsky MI; Davis N; Kalebasty AR; Picus J; Shaffer D; Mao S; Adra N; Yorio J; Gandhi S; Grivas P; Siefker-Radtke A; Yang R; Latven L; Olson P; Chin CD; Der-Torossian H; Mortazavi A; Iyer G
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38105142
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
Galsky MD; Saci A; Szabo PM; Han GC; Grossfeld G; Collette S; Siefker-Radtke A; Necchi A; Sharma P
Clin Cancer Res; 2020 Oct; 26(19):5120-5128. PubMed ID: 32532789
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Tural D; Ölmez ÖF; Sümbül AT; Artaç M; Özhan N; Akar E; Çakar B; Köstek O; Ekenel M; Erman M; Coşkun HŞ; Selçukbiricik F; Keskin Ö; Türköz FP; Oruç K; Bayram S; Yılmaz U; Bilgetekin İ; Yıldız B; Şendur MAN; Paksoy N; Dirican A; Erdem D; Selam M; Tanrıverdi Ö; Paydaş S; Urakçı Z; Atağ E; Güncan S; Ürün Y; Alkan A; Kaya AO; Özyükseler DT; Taşkaynatan H; Yıldırım M; Sönmez M; Başoğlu T; Gündüz Ş; Kılıçkap S
Eur Urol Focus; 2021 Sep; 7(5):1061-1066. PubMed ID: 33008789
[TBL] [Abstract][Full Text] [Related]
18. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Ying J; Han W; Hu C; Ling Y; Chi Z; Cui C; Si L; Fang J; Zhou A; Guo J
Clin Cancer Res; 2021 Jan; 27(1):43-51. PubMed ID: 33109737
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
Sharma P; Siefker-Radtke A; de Braud F; Basso U; Calvo E; Bono P; Morse MA; Ascierto PA; Lopez-Martin J; Brossart P; Rohrberg K; Mellado B; Fischer BS; Meadows-Shropshire S; Abdel Saci ; Callahan MK; Rosenberg J
J Clin Oncol; 2019 Jul; 37(19):1608-1616. PubMed ID: 31100038
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Matsubara N; de Wit R; Balar AV; Siefker-Radtke AO; Zolnierek J; Csoszi T; Shin SJ; Park SH; Atduev V; Gumus M; Su YL; Karaca SB; Cutuli HJ; Sendur MAN; Shen L; O'Hara K; Okpara CE; Franco S; Moreno BH; Grivas P; Loriot Y
Eur Urol; 2024 Mar; 85(3):229-238. PubMed ID: 37778952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
